Lonsurf (trifluridine/tipiracil)
Status:
Concluded with an LOI
Manufacturer:
Taiho Pharma Canada Inc.
Indication:
Metastatic Colorectal Cancer
Last updated August 8, 2019
Fibristal (ulipristal acetate)
Status:
Concluded with an LOI
Manufacturer:
Allergan Inc.
Indication:
Uterine fibroids (signs and symptoms)
Last updated August 6, 2019
Status:
Negotiations were not pursued
Manufacturer:
Takeda Canada Inc.
Indication:
Multiple Myeloma
Last updated August 2, 2019
Arbesda RespiClick (fluticasone propionate/salmeterol xinafoate)
Status:
Concluded without agreement
Manufacturer:
Teva Canada Ltd.
Indication:
Asthma
Last updated July 31, 2019
Aermony Respiclick (fluticasone propionate)
Status:
Concluded without agreement
Manufacturer:
Teva Canada Ltd.
Indication:
Asthma
Last updated July 31, 2019
Status:
Concluded with an LOI
Manufacturer:
Novo Nordisk Canada Inc.
Indication:
Diabetes Mellitus, Type 2
Last updated July 26, 2019
Status:
Concluded without agreement
Manufacturer:
Amgen Canada Inc.
Indication:
Primary hyperlipidemia and mixed dyslipidemia
Last updated July 25, 2019
Status:
Concluded with an LOI
Manufacturer:
Vertex Pharmaceuticals (Canada) Incorporated
Indication:
Cystic Fibrosis In Patients with CFTR Gating Mutations or the R117H Gating Mutation
Last updated July 17, 2019
Status:
Negotiations were not pursued
Manufacturer:
Ipsen Biopharmaceuticals Canada, Inc.
Indication:
Carcinoid Syndrome
Last updated July 12, 2019
Status:
Concluded with an LOI
Manufacturer:
Pfizer Canada ULC
Indication:
Rheumatoid Arthritis
Last updated July 9, 2019